Related Experiment Video
Updated: Apr 30, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Human tumor xenograft models for preclinical assessment of anticancer drug development
1College of Pharmacy, Duksung Women's University, Seoul, Korea.
Abstract:
Xenograft models of human cancer play an important role in the screening and evaluation of candidates for new anticancer agents. The models, which are derived from human tumor cell lines and are classified according to the transplant site, such as ectopic xenograft and orthotopic xenograft, are still utilized to evaluate therapeutic efficacy and toxicity. The metastasis model is modified for the evaluation and prediction of cancer progression. Recently, animal models are made from patient-derived tumor tissue. The patient-derived tumor xenograft models with physiological characters similar to those of patients have been established for personalized medicine. In the discovery of anticancer drugs, standard animal models save time and money and provide evidence to support clinical trials. The current strategy for using xenograft models as an informative tool is introduced.
Insights
Xenograft models are crucial for testing new anticancer drugs, offering cost-effective evaluation and predicting cancer progression. Patient-derived xenografts advance personalized medicine by mimicking patient physiology.
Area of Science:
- Oncology
- Preclinical Research
- Drug Discovery
Background:
- Xenograft models are vital tools in oncology for evaluating novel anticancer agents.
- These models, including ectopic and orthotopic xenografts, assess therapeutic efficacy and toxicity.
- Metastasis models aid in predicting cancer progression.
Purpose of the Study:
- To introduce the current strategy for utilizing xenograft models in anticancer drug discovery.
- To highlight the role of xenografts in screening and evaluating new therapeutic candidates.
- To discuss the evolution towards patient-derived xenografts for personalized medicine.
Main Methods:
- Classification of xenograft models based on transplant site (ectopic, orthotopic).
- Development of metastasis models for cancer progression evaluation.
- Establishment of patient-derived tumor xenografts (PDTX) for personalized approaches.
Main Results:
- Standard xenograft models streamline drug discovery, saving time and resources.
- PDTX models offer enhanced physiological relevance, mirroring patient conditions.
- Xenografts provide critical data supporting the progression to clinical trials.
Conclusions:
- Xenograft models remain indispensable in the preclinical evaluation of anticancer drugs.
- Patient-derived xenografts represent a significant advancement for personalized cancer therapy.
- Strategic use of xenografts accelerates the development of effective cancer treatments.
More Related Videos
09:43Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
Published on: May 17, 2017
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
